Table 1 Drug-induced growth inhibition in EOC cells in 4 treatment groups

From: Atractylenolide-I Sensitizes Human Ovarian Cancer Cells to Paclitaxel by Blocking Activation of TLR4/MyD88-dependent Pathway

  

SKOV3 cells

A2780 cells

Treatment group

n

IC50 (μmol/L)

P*

IC50 (μmol/L)

P*

AO-1

3

>100

-

>100

-

Paclitaxel

3

0.038 ± 0.004

-

0.024 ± 0.004

-

Paclitaxel/AO-I

3

0.011 ± 0.004*

0.027

0.029 ± 0.006

0.500

Paclitaxel/LPS

3

0.082 ± 0.002*

0.044

0.033 ± 0.004

0.100

  1. EOC cells were treated with vehicle or paclitaxel plus AO-I (100 μmol/L) or paclitaxel plus LPS (1 μg/ml) for 72 hours. Relative number of viable cells was assayed using MTT. IC50 values were measured as a curvilinear regression equation for each survival curve. Data represent mean values ± S.D. from three independent experiments.
  2. *P values, compared with paclitaxel alone.
Back to article page